Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

Kanae Yumimoto; Shigeaki Sugiyama; Koshi Mimori; Keiichi I. Nakayama

doi:10.1111/cas.14075

Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

Kanae Yumimoto, Shigeaki Sugiyama, Koshi Mimori, Keiichi I. Nakayama

Research output: Contribution to journal › Review article › peer-review

39 Citations (Scopus)

Abstract

Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

Original language	English
Pages (from-to)	2090-2099
Number of pages	10
Journal	Cancer Science
Volume	110
Issue number	7
DOIs	https://doi.org/10.1111/cas.14075
Publication status	Published - Jul 2019

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.14075

Cite this

@article{827ea48084004a26bdae92dd539eaebb,

title = "Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents",

abstract = "Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.",

keywords = "CCL2, CCR2, inflammation, metastasis, propagermanium",

author = "Kanae Yumimoto and Shigeaki Sugiyama and Koshi Mimori and Nakayama, \{Keiichi I.\}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Cancer Science published by John Wiley \& Sons Australia, Ltd on behalf of Japanese Cancer Association.",

year = "2019",

month = jul,

doi = "10.1111/cas.14075",

language = "English",

volume = "110",

pages = "2090--2099",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

AU - Yumimoto, Kanae

AU - Sugiyama, Shigeaki

AU - Mimori, Koshi

AU - Nakayama, Keiichi I.

PY - 2019/7

Y1 - 2019/7

N2 - Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

AB - Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

KW - CCL2

KW - CCR2

KW - inflammation

KW - metastasis

KW - propagermanium

UR - https://www.scopus.com/pages/publications/85068553751

UR - https://www.scopus.com/inward/citedby.url?scp=85068553751&partnerID=8YFLogxK

U2 - 10.1111/cas.14075

DO - 10.1111/cas.14075

M3 - Review article

C2 - 31111571

AN - SCOPUS:85068553751

SN - 1347-9032

VL - 110

SP - 2090

EP - 2099

JO - Cancer Science

JF - Cancer Science

IS - 7

ER -

Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this